Dr. Reddy’s Tops Billion Dollar Mark In First Nine Months Of Fiscal 2007
This article was originally published in The Pink Sheet Daily
Executive Summary
Indian generic drug maker achieved the milestone on acquisitions supported by a “strong and profitable” growth engine.
You may also be interested in...
Indian Companies Ramping Up For Follow-On Biologics
Like Western companies, Indian drug makers are buying or forming alliances with biotechs to enrich their pipelines but with the added goal of ramping up to do what they currently do best: create generic versions of branded drugs
Indian Companies Ramping Up For Follow-On Biologics
Indian pharma firms are expected to be active in filing for biosimilar approvals, Ranbaxy exec tells “The Pink Sheet” DAILY
Indian Companies Ramping Up For Follow-On Biologics
Indian pharma firms are expected to be active in filing for biosimilar approvals, Ranbaxy exec tells “The Pink Sheet” DAILY